KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2023 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $341.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 16.6% year-over-year to $341.2 million, compared with a TTM value of $341.2 million through Dec 2025, down 16.6%, and an annual FY2025 reading of $341.2 million, down 16.6% over the prior year.
  • Total Non-Current Liabilities was $341.2 million for Q4 2025 at Recursion Pharmaceuticals, down from $351.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $409.1 million in Q4 2024 and bottomed at $188.4 million in Q2 2024.
  • Average Total Non-Current Liabilities over 3 years is $303.4 million, with a median of $346.4 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities soared 115.01% in 2024, then decreased 16.6% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $190.3 million in 2023, then skyrocketed by 115.01% to $409.1 million in 2024, then fell by 16.6% to $341.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RXRX at $341.2 million in Q4 2025, $351.5 million in Q3 2025, and $381.6 million in Q2 2025.